Phase III trials of Amphocil amphotericin B colloidal dispersion are "about to begin," VP-Research Francis Martin, PhD, tells the Mabon Securities Drug Delivery Conference Feb. 19 in New York City. The company forecasts an NDA filing for the first quarter of 1993 for treatment of life-threatening fungal infections in patients who have failed conventional therapy. A second NDA, for the "Stealth" liposome encapsulated doxorubicin Doxil for the treatment of Kaposi's sarcoma, is slated for mid-1993, Martin says.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth